Morningstar
•
Nov 02, 2026
Sanofi: Sanofi Earnings: Guidance Upgraded as Pharma Launches and Dupixent Drive Growth
Summary
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Regeneron Pharmaceuticals, Inc.
Nov 02, 2026
•
REGN
Technical Assessment: Bullish in the Intermediate-Term
Nov 02, 2026
•
CVX, TEVA
Analyst Report: AstraZeneca PLC
Nov 02, 2026
•
AZN
Analyst Report: Regeneron Pharmaceuticals, Inc.
Oct 30, 2026
•
REGN
Analyst Report: Gilead Sciences, Inc.
Oct 30, 2026
•
GILD
